반응식
[OH:1][C:2]1[CH:3]=[CH:4][C:5]([O:8][C:9]2[CH:19]=[CH:18][C:12]([CH2:13][NH:14][C:15](=[O:17])[CH3:16])=[CH:11][CH:10]=2)=[N:6][CH:7]=1.Br[C:21]1([CH2:30][CH2:31][O:32][CH2:33][CH3:34])[C:26](=[O:27])[NH:25][C:24](=[O:28])[NH:23][C:22]1=[O:29].CCCCC=CCCCC.C1(F)(C2(F)OC(C(F)(F)F)(C(F)(F)F)OC2(F)F)OC(C(F)(F)F)(C(F)(F)F)OC1(F)F>C(#N)C>[CH2:33]([O:32][CH2:31][CH2:30][C:21]1([O:1][C:2]2[CH:3]=[CH:4][C:5]([O:8][C:9]3[CH:19]=[CH:18][C:12]([CH2:13][NH:14][C:15](=[O:17])[CH3:16])=[CH:11][CH:10]=3)=[N:6][CH:7]=2)[C:22](=[O:29])[NH:23][C:24](=[O:28])[NH:25][C:26]1=[O:27])[CH3:34]참가 물질
6
반응물 4
생성물 1
시약·촉매·용매 1
실험 절차
Following the procedure outlined for the preparation of Example 1, N-[4-(5-hydroxy-pyridin-2-yloxy)-benzyl]-acetamide (0.25 g, 0.97 mmol) when treated with 5-bromo-5-(2-ethoxy-ethyl)-pyrimidine-2,4,6-trione (0.20 g, 0.80 mmol), 1,5,7-trazabicyclo[4.4.0]dec-5-ene bound to polystyrene crosslinked with 2% DVB (PTBD, Fluka, 0.77 g) and 4 mL of acetonitrile, will afford N-(4-{5-[5-(2-Ethoxy-ethyl)-2,4,6-trioxo-hexahydro-pyrimidin-5-yloxy]-pyridin-2-yloxy}-benzyl)-acetamide. Expected MS (m/z, APCI): 455 [M−H]−.
출처 및 근거
- ORD 기록
- ord-bc577369023b4913b868e1fc7169472e
- 출처 데이터셋
- uspto-grants-2004_03
- 특허 번호
- US06706723B2
연결된 노트
불러오는 중…